Core Viewpoint - The article discusses the growing market for lactoferrin, particularly human-derived recombinant lactoferrin, highlighting its potential applications in infant formula and health supplements, as well as the challenges faced by companies in this sector [2][3][5]. Market Overview - The global market for lactoferrin is approximately $700 million, with an expected annual growth rate exceeding 7% [2]. - The primary application of lactoferrin is in infant formula, which accounts for nearly half of the total market share. Other applications include dietary supplements, pharmaceuticals, and functional foods [2]. - Japan is the largest market for lactoferrin, holding over 50% of the market share, followed by China, North America, and Europe, which collectively account for over 30% [2]. Company Insights - Beijing Guoke Xinglian Technology Co., Ltd. (Guoke Xinglian) is a leading company in the field of synthetic human active proteins, recently completing a financing round of over 100 million yuan to promote the industrialization and global marketing of its core functional protein/peptide products [2][3]. - Guoke Xinglian focuses on the innovative research of human homologous lactoferrin and utilizes microbial fermentation technology to produce functional human proteins, addressing key technological bottlenecks in the health and alternative protein sectors [3]. Technological Advancements - The preparation of human homologous lactoferrin is challenging due to the need to replicate its human glycosylation structure, which affects protein folding, stability, and functionality [4]. - Guoke Xinglian is the only company globally that uses food-grade yeast to express human homologous glycoproteins, positioning itself as a leader in the next generation of "human homologous" protein products [4][7]. Regulatory Landscape - Recombinant lactoferrin is accelerating its breakthrough through regulatory barriers, becoming a focal point in the global nutrition and health industry [7]. - As global regulatory frameworks improve, recombinant lactoferrin is transitioning from laboratory research to market availability, potentially reshaping the industry landscape for infant nutrition, immune therapy, and chronic disease management [7].

Core Viewpoint - The article emphasizes the importance of the Bio-based Young Scientists Forum as a platform for young researchers in the bio-based materials industry to showcase their innovations and connect with industry stakeholders, thereby enhancing their visibility and opportunities for collaboration [4][35]. Group 1: Importance of the Forum - The bio-based industry is experiencing explosive growth, with a reported increase of 29.8% in the first three quarters of 2025 and a monthly growth of 25.4% in November [9][10]. - Young researchers face a dilemma with a low funding success rate of 14-16% for national science projects, making it crucial to establish visibility in the industry [11][12]. - There is a significant gap in the commercialization of academic patents, with only 3.9% of university patents being industrialized compared to nearly 50% for enterprises, highlighting the need for better connections between academia and industry [14]. Group 2: Benefits of Participation - Participants will have a 10-minute platform to present their cutting-edge technologies, allowing for concise communication of their core innovations [15][16]. - The forum provides expert reviews and feedback from authoritative figures in the field, with awards for outstanding presentations, including a first prize of 2000 yuan [18][19]. - There will be real opportunities for industry connections, with over 1000 successful matches in the bio-based sector previously facilitated by the organizing company [20]. - Participants will receive dedicated promotional support, including custom posters and social media exposure, reaching over 200,000 individuals across various sectors [21][23]. Group 3: Target Audience - The forum is aimed at young scholars with research achievements in bio-based chemicals, materials, and additives, as their work may align with the needs of chemical companies undergoing transformation [26][28]. Group 4: Participation Details - The forum will take place on May 20, 2026, in Shanghai, as part of the 11th Bio-based Conference and Exhibition [30]. - Registration is straightforward, requiring participants to select the "Young Scientists Forum" option when signing up [31].

Core Viewpoint - The article discusses the development of a cost-effective biobased method for producing 3-hydroxypropanoic acid (3-HP) using genetically engineered microorganisms, highlighting its commercial potential and environmental benefits [2][3][5]. Group 1: Research and Development - Scientists from the University of Illinois and Penn State University have cultivated a high-yield strain of Issatchenkia orientalis for 3-HP production, confirming its commercial viability through technical economic analysis (TEA) and life cycle assessment (LCA) [3][5]. - The research team identified the β-alanine metabolic pathway as the optimal choice for maximizing 3-HP yield, with the lowest oxygen demand [5][6]. - The team achieved a 3-HP production yield of 29 g/L in shake flask fermentation and 92 g/L in fed-batch fermentation, surpassing previous commercial viability thresholds [6][8]. Group 2: Economic and Environmental Impact - The commercial potential of 3-HP is significant, with the acrylic acid market valued at approximately $20 billion and a global demand of about 6.6 million tons in 2019 [4]. - The estimated minimum product selling price (MPSP) for acrylic acid produced from pure glucose is $1.36/kg, which can be reduced to $1.13/kg when integrating the entire production chain with on-site corn dry milling [8]. - The carbon intensity of the corn-based route is 3.26 kg CO₂ equivalent/kg acrylic acid, which is lower than fossil-based acrylic acid in 98.5% of simulated scenarios [8][20]. Group 3: Future Directions - The research team plans to scale up the process, refine downstream operations, and incorporate other renewable feedstocks to enhance overall economic viability [9]. - CABBI researchers are exploring additional applications for 3-HP, such as its conversion into maleic acid and other high-value chemicals for use in vitamins, pharmaceuticals, biodegradable plastics, and agricultural chemicals [9].

使用蛋白质制造纤维的想法并不新鲜，但过去的尝试未能与合成材料竞争。 例如， Lanital 是20世纪30年代从牛奶蛋白中开发的一种材料， 当聚酯出现时，由于强度低而失宠。 最终， 早期的生物纤维(如来自花生和玉米蛋白的纤维)无法克服低性能和高成本的双重挑战，让廉价、坚固的聚酯占据了市场。 在这项新的研究中， 蛋白质从酵母中提取出来，溶解在溶剂中 ，并通过 喷丝头 形成连续纤维，然后纺成纱线。 /DT 生物基纺织鞋服 交流群/ 让专业的人聚在一起, 生物基纤维/纺织印染/品牌终端等产业同行❤️↓ 【SynBioCon】 获 悉，一项新的研究表明，可以用生产啤酒、葡萄酒或药品后剩下的废酵母来制造结实的服装纤维。 酒精和药物生产后剩余的酵母生物质由蛋白质、脂肪和糖等元素组成，通常被归类为副产品或废物。 美国宾夕法尼亚州立大学的研究人员从这种废料 中开发出了一种可持续的蛋白质纤 维 。 据报道，由此产生的纤维比天然纤维更坚固，每公斤的生产成本为6美元或更低(相比之下，羊毛的生产成本为10-12美元)。 有趣的是，它有可能解决世界饥饿和快时尚对环境的影响。 从废酵母中提取出来的 蛋白质纤维 关键词 | 绿色化工和新材 ...

Core Viewpoint - Guangdong Province aims to enhance the bio-manufacturing industry, targeting a total output value of approximately 500 billion yuan by 2027 and reaching a trillion yuan scale by 2035, focusing on key areas such as non-grain utilization, medical beauty raw materials, microbial proteins, and green processes in biopharmaceuticals [2][3][4]. Group 1: Policy Measures and Goals - The action plan specifies the development goals for the bio-manufacturing industry in Guangdong, aiming for a total output value of around 500 billion yuan by 2027 and a trillion yuan scale by 2035 [2][3]. - The measures address key bottlenecks in bio-manufacturing, including the need for improved standards and ecosystem development [4][6]. Group 2: Key Initiatives - The policy outlines detailed initiatives to tackle issues such as an incomplete industrial chain and lagging standard system construction, emphasizing the establishment of a comprehensive bio-manufacturing industry standard system [6]. - It encourages the establishment of innovation platforms and supports the construction of transformation bases for innovative achievements, promoting technology transfer and application [6]. Group 3: Focus Areas for Development - The measures focus on core technology breakthroughs, including strains, enzyme preparations, and reactors, as well as high-end platform construction and targeted R&D mechanisms [7]. - The policy emphasizes the importance of building a robust standard system that includes both domestic and international standards, facilitating market access and internationalization [7]. Group 4: Applications in Bio-Manufacturing - The initiative aims to advance non-grain bio-based materials, medical beauty products, and "new food" categories, promoting the use of microbial proteins and plant-based proteins [8][9]. - In the pharmaceutical sector, the policy encourages the application of bio-manufacturing in green process development for biopharmaceuticals and the synthesis of effective components from traditional Chinese medicine [9]. Group 5: Internationalization Strategies - The policy outlines strategies for internationalization, including aligning with international standards organizations and expanding overseas markets through e-commerce and overseas warehouses [10]. - It emphasizes the importance of attracting key domestic and international enterprises and high-end R&D institutions to build a global resource collaboration network [10]. Group 6: Regional Development and Innovation - Guangdong Province implements a "dual-core drive" strategy, focusing on Guangzhou and Shenzhen to accelerate the development of the bio-manufacturing industry in the Greater Bay Area [11]. - The policy supports the establishment of a comprehensive support system for bio-manufacturing, covering research, pilot testing, and industrialization [11].

Core Viewpoint - Zhuhai Maidefa Biotechnology Co., Ltd. (referred to as "Maidefa") has successfully completed a Series B financing round, which is a recognition of its technological strength and market prospects, as well as an important step in accelerating its industrialization process [2][6]. Group 1: Financing Events - Maidefa completed its angel round financing in March 2021, followed by a Series A financing of tens of millions of RMB in May 2022, and a Series A+ financing of several tens of millions of RMB in December 2023 [5]. - The recent Series B financing was led by China Taiping Innovation and Guangzhou Pharmaceutical Capital, with specific amounts undisclosed [2][6]. Group 2: Company Positioning - Maidefa's name "MedPHA" combines "Medicine" and "PHA," indicating its unique positioning as an innovative enterprise in the "medicine + PHA" sector, rather than just a PHA materials company [7]. - The third-largest shareholder, Lijuzhiyuan Pharmaceutical Group Co., Ltd., has been involved with Maidefa since its inception, indicating a deep-rooted strategic partnership rather than a mere financial investment [10]. Group 3: Product Lines - Maidefa has three major product lines: industrial-grade PHA, medical-grade PHA, and beta-hydroxybutyrate (β-hydroxybutyric acid) health-active small molecules, forming a complete PHA value chain [15]. - The industrial-grade PHA includes PHB and P34HB, which are recognized by major companies like Walmart and Costco for applications in biodegradable packaging and utensils [18]. - The medical-grade PHA is a core differentiated product, with Maidefa being the first global supplier to receive regulatory approvals from the National Medical Products Administration and the FDA [19]. - The beta-hydroxybutyric acid product, branded as "Sainao Si," has been launched in Macau and the United States, targeting markets in brain health and anti-aging [20]. Group 4: Milestones - Maidefa achieved significant milestones in 2025, including medical certifications, capacity expansions, and the completion of Series B financing [23]. - The company expanded its industrial-grade PHA production capacity to over 2,000 tons with a new production line in Zhanjiang, which began operations in early 2025 [25]. - Maidefa became the first in China to obtain documentation for medical-grade PHA microspheres, which will serve clinical applications in absorbable medical devices [27]. - The company also received ISO13485:2016 certification for its medical device quality management system, marking a key qualification for entering the medical device market [27].

Core Viewpoint - The article discusses the signing of a straw bioconversion project in Baoying County, highlighting the investment and production capacity of the project, which aims to utilize agricultural waste for sustainable feed production [2][4]. Group 1: Project Overview - The straw bioconversion project has a planned total capacity of 600,000 tons and a total investment of 1 billion yuan, with the first phase covering approximately 60 acres and involving the construction of a 30,000 square meter factory [2]. - The first phase includes an investment of 80 million yuan for a production line capable of converting 150,000 tons of straw into fermented feed, projected to generate annual sales exceeding 300 million yuan and tax contributions over 8 million yuan [2]. - The second phase plans to invest in a production line for 200,000 tons of straw-derived single-cell protein feed [2]. Group 2: Company Background - Zhongke Kangyuan (Tangshan) Biotechnology Co., Ltd. was founded by Dr. Zhang Dongyuan, a researcher from the Tianjin Institute of the Chinese Academy of Sciences, and is recognized as a "National High-tech Enterprise" and a "Specialized and Innovative Enterprise" in Hebei Province [4]. - The company focuses on the research and development of biomass depolymerization molecular chemical processes, having established two provincial R&D platforms and one production base with a capacity of 200,000 tons [4]. - Zhongke Kangyuan has participated in 14 research projects, including one that is part of three national key R&D projects, and holds 36 national intellectual property patents [4]. Group 3: Investment and Financing - Zhongke Kangyuan completed its first round of financing in December 2025, successfully attracting strategic investors including the National Development Investment Group and Wuxi Innovation Investment Group [5].

Core Viewpoint - Cardiovascular diseases are a major public health challenge in China, with a high mortality rate and increasing prevalence among younger populations. The study highlights the importance of exploring fat control solutions that align with Chinese cooking habits, particularly focusing on the use of diacylglycerol (DAG) oil as a healthier alternative to traditional triglyceride (TAG) oil [3][4]. Group 1: Research Findings - A recent study published in the journal "Food & Function" by a team from Peking University Medical School demonstrated that replacing traditional TAG oil with DAG oil in daily diets significantly improves lipid metabolism in the Chinese population [4][6]. - The study involved 120 Chinese adults with a BMI of 25.93±2.92 kg/m², who were randomly assigned to either the DAG group or the TAG group for an 8-week dietary intervention. Results showed that the DAG group had significantly lower serum triglycerides (TG), total cholesterol (TC), and small dense low-density lipoprotein cholesterol (sdLDL-C) levels compared to the TAG group [6][9]. - Notably, the DAG group experienced a significant reduction in visceral fat area (VFA) and improvements in liver fat degeneration, indicating potential benefits for non-alcoholic fatty liver disease [6][9]. Group 2: Clinical Significance - The study is the first to systematically validate the effects of DAG oil on key lipid indicators in the Chinese population, particularly its ability to lower sdLDL-C, which is a strong predictor of atherosclerosis and ischemic stroke [7][9]. - The research emphasizes the multi-mechanism benefits of DAG, highlighting its role in reducing visceral fat, which is a core risk factor for metabolic syndrome, type 2 diabetes, and cardiovascular diseases [9][14]. - Lipidomic analysis revealed that DAG intervention led to significant increases in triglycerides and phosphatidylethanolamine rich in monounsaturated and polyunsaturated fatty acids, which are associated with the activation of fat breakdown and thermogenesis pathways [11][14]. Group 3: Implications for Public Health - The findings fill an important evidence gap regarding the health effects of DAG oil in the Chinese population, aligning with the dietary habits of "no oil, no dish" prevalent in Chinese cooking [14]. - Promoting the use of DAG oil represents a practical health choice that does not require changes in cooking habits, potentially improving metabolic health and reducing cardiovascular risks simply by switching oils [14].

Core Insights - The article highlights the significant potential of bacterial cellulose (BC) as a natural material produced through microbial fermentation, showcasing its applications in next-generation energy storage devices and various high-growth sectors [2][3]. Company Overview - Yuan Dong Biotechnology Co., Ltd., established in January 2024, has rapidly gained attention from several renowned institutions and focuses on the synthesis of bacterial nanocellulose (BC/BNC) materials [3]. - The company has developed a globally leading production system for bacterial nanocellulose by integrating synthetic biology and artificial intelligence, reducing the production cycle from 10 days to 48 hours [3]. Product and Market Strategy - Yuan Dong is achieving industrial-scale production of high-purity nanocellulose, which meets international standards, particularly in the display materials sector, reducing reliance on imports and enhancing the security of the national display industry chain [5]. - The company has introduced a revolutionary "biological nanocrystalline gel" for the cosmetics industry, which addresses the long-standing reliance on chemical additives and offers natural preservation capabilities, significantly reducing allergenic risks [5]. - This innovative material has entered the supply chains of several well-known cosmetic companies, aiming to make safe and effective biobased products accessible to the general public at more affordable prices [5]. Industry Trends - The article notes that by 2030, it is expected that at least 20% of petroleum-based products will be replaced by biobased products, driven by companies like Yuan Dong that leverage technology to enhance quality of life and promote sustainable practices [6]. Upcoming Events - The 11th Bio-based Industry Conference & Exhibition will take place from May 20-22, 2026, in Shanghai, featuring 11 thematic forums and 7 concurrent activities aimed at exploring innovation and collaboration in the biobased industry [7][8].

Core Viewpoint - 恒碳科技 is participating in the 2026 DT New Leaf Award, showcasing its innovative biobased products and technologies, particularly in the production of biobased 1,3-propanediol (PDO) [2][18]. Group 1: Company Overview - 恒碳科技 focuses on "carbon science and carbon balance," producing high-value chemicals and high-performance materials, with its Biebl® biobased PDO achieving a purity of 99.98% and near-zero carbon emissions [3]. - The company has successfully crossed the "valley of death" in pilot testing and has commenced production at its PDO manufacturing base, which has an annual capacity of 15,000 tons [9][10]. Group 2: Technological Innovations - 恒碳科技 employs a revolutionary "three non-four no" technology developed by a team led by Professor Zeng Anping, significantly reducing production costs and enhancing efficiency and stability [5]. - The PDO production process achieves a glycerol conversion rate of over 0.52 g/g, with theoretical carbon emissions of only 0.015 kg CO2/kg, resulting in a reduction of 1.2 kg CO2 per kilogram of PDO, totaling an annual carbon reduction of 18,000 tons [11]. Group 3: Market Expansion and Applications - The company is expanding its biobased PDO applications, having launched BIODEX® non-grain biobased PTT fibers and a fully biodegradable plastic made from biobased PDO, addressing plastic pollution in the fashion industry [12]. - 恒碳科技 is actively promoting its biobased PDO internationally, establishing strategic partnerships, such as with DEEWIG GmbH in Germany, to enhance its market presence in Europe [12]. Group 4: Awards and Recognition - 恒碳科技's production technology has been recognized as world-leading in Guangdong Province, and the company has received multiple international certifications, including USDA and REACH [13]. - The company won the "Most Commercially Valuable Award" at the third New Leaf Award, highlighting its innovative leadership in the biobased sector [18].